Core Viewpoint - The CEO of Aikang Group, Zhang Ligang, emphasized the clear distinction between health check-ups and medical consultations, stating that health check-ups are primarily for disease prevention and risk identification, while medical consultations are for definitive diagnosis and treatment [1][4]. Group 1: Media Misrepresentation - Some media outlets misinterpreted Zhang Ligang's comments, reducing them to the phrase "don't expect a few hundred yuan check-up to detect any illness," which stripped the context and distorted the original meaning [1][2][4]. - The media's simplification of the discussion on the differences between health check-ups and medical consultations misled the public regarding the value of health check-ups, violating principles of objective and comprehensive reporting [2][4]. Group 2: Commitment to Professionalism - Aikang Group asserts that it will not compromise the professionalism of its services, regardless of the price of health check-up packages, maintaining a commitment to customer-centric health management services [2][5]. - The company aims to provide rigorous health management services and emphasizes that the cost of check-up packages does not affect the quality of service provided [2][5].

近日，律师张女士称十年体检未有"患癌风险"预警，确诊已是肾癌晚期。对此，7月30日，爱康国宾举办媒体说明 会。南都N视频记者获悉，爱康国宾有关负责人否认"假体检"，并称爱康已向人民法院提起诉讼，获法院受理并 立案。对此，张女士回应，要求把自己的10年超声检查、检查人员名单和资质、第三方机构、起诉内容等情况对 外公布。 爱康国宾称已起诉 "体检要做什么项目，某种程度不是医生说了算的，是公司人事部说了算的。所以到体检中心做体检，套餐里有什 么就是做什么。"围绕体检、看病间的区别这一话题，爱康集团创始人、董事长兼CEO张黎刚称，在看病模式下， 病人做什么项目，不是套餐说了算，而是专科医生说了算。如果体检按照看病模式来的话，可能一两天都查不 完。"体检模式是帮你发现各种问题后，体检医生详细描述发现的问题，做一定的风险提示，最终你应该去找专科 医生来进行确诊。" 张黎刚表示，"大家想一下，大多数企业给员工做体检，少的几百块，多的也就几千块钱。大家去医院看个病，你 要诊断某个病，你们问问自己，大概要花多少钱。当你指望说，一个几百块钱的体检能帮你什么病都查出来，而 要查单一的病，都花几千几万块钱的时候，你认为这样的情况存在 ...

近日，律师张女士称十年体检未有"患癌风险"预警，确诊已是肾癌晚期。对此，7月30日，爱康国宾举 办媒体说明会。 ...

Core Viewpoint - The controversy surrounding Aikang Guobin's health check services has intensified following allegations from lawyer Zhang Xiaoling regarding missed cancer diagnoses, leading to a formal lawsuit by the company against her for defamation [1][5][14] Group 1: Company Response - Aikang Guobin reiterated that there were no missed or erroneous diagnoses in Zhang's health checks and has filed a lawsuit for defamation based on her claims of "fabricating facts and spreading rumors" [1][5] - The company presented Zhang's 2023 health check report, which indicated potential issues but recommended further examinations, emphasizing the importance of regular follow-ups [3][4] - Aikang Guobin's CEO, Zhang Ligang, clarified that health checks are meant for risk assessment rather than definitive diagnoses, highlighting the limitations of low-cost health check packages [6][10] Group 2: Public and Media Reaction - Zhang Xiaoling has publicly welcomed the lawsuit and has called for Aikang Guobin to disclose her ten years of health check data, including ultrasound images and technician qualifications [4][5] - The company's statements regarding the nature of health checks have sparked significant public debate, with some media misrepresenting the CEO's comments, leading to accusations of defamation against the company [6][11][12] - Aikang Guobin reported a high volume of complaints on platforms like Black Cat Complaints, with 76.2% attributed to uncontrollable factors, while only 2.5% were related to medical service issues [14]

Core Viewpoint - The company, Aikang Group, has responded to allegations from a lawyer, Ms. Zhang, regarding a failure to detect kidney cancer during her ten years of health check-ups, asserting that there were no misdiagnoses or missed diagnoses in her medical evaluations [1][3][9] Group 1: Company Response - Aikang Group held a media briefing to address the claims made by Ms. Zhang, stating that an internal and external review confirmed the accuracy of her kidney examinations [1][3] - The company has filed a formal lawsuit against Ms. Zhang regarding her allegations, which has been accepted by the court [1][9] - Aikang Group provided detailed information about Ms. Zhang's health check data, equipment information, and quality control results to the relevant authorities [7] Group 2: Medical Evaluation Details - During her health check on October 9, 2023, at Aikang Group's Beijing West Branch, Ms. Zhang's ultrasound report indicated potential issues, including a left kidney hamartoma and a calcified lesion on the right kidney, with recommendations for further examination [3][8] - The company clarified that the cancer embryonic antigen (CEA) test, which Ms. Zhang referenced, is not relevant for early diagnosis of kidney cancer, as early detection primarily relies on imaging techniques [8]

Core Viewpoint - The company, Aikang Guobin, is taking legal action against a lawyer, Zhang, who claimed that her cancer was undetected during ten years of health check-ups, asserting that her allegations are false and damaging to the company's reputation [1][3]. Group 1: Company Response - Aikang Guobin has filed a lawsuit against Zhang for defamation, stating that her claims have harmed the dignity of its employees and misled the public about the private health examination industry [1][3]. - The company clarified that Zhang's health check-ups were part of a basic welfare package provided by the Beijing Lawyers Association, and she did not opt for any additional paid services except in 2017 [3]. - Aikang Guobin presented evidence from Zhang's recent health check-up, indicating the possibility of a renal tumor, and emphasized that the purpose of health examinations is to identify risk signals rather than provide definitive diagnoses [3][4]. Group 2: Industry Context - The company highlighted that over 4.8 million new cancer cases are diagnosed annually in China, with Aikang Guobin identifying approximately 15,000 cases, equating to one in every 320 diagnosed cancer patients [3]. - There have been multiple complaints against Aikang Guobin regarding inaccurate health reports and misdiagnoses, with a total of 1,220 complaints recorded on a consumer complaint platform [9]. - The company has undergone internal reviews and external expert evaluations, concluding that it bears no responsibility for Zhang's case and is open to third-party assessments [9].

"女律师体检10年未提示癌症"的体检门事件持续发酵。7月30日，身陷信任危机的爱康国宾官宣强势回 击动作。 在7月30日举行的媒体说明会上，爱康集团就"10年体检未预警肾癌"事件进行回应和澄清。会上爱康集 团高管郑重宣布：已就张女士虚构事实、散布谣言的侵权行为向法院提起正式诉讼，并获法院受理并立 案。 "张女士本应秉持职业操守，她却罔顾事实，通过造谣污蔑手段，通过网络媒体大肆发酵爱康国宾假体 检言论，开展了一场对爱康有组织的网暴。由于其行为严重损害爱康声誉，让每年约800万体检客户蒙 羞，更让民众对私营体检中心，乃至中国整个医疗行业产生不信任。在上述情况下，爱康认为，必须要 澄清事实，还原真相，爱康代表1.5万名爱康员工，向人民法院提请诉讼，现已正式立案受理。"公司高 管在会上表示。 对于爱康国宾今日的发布会，当事人张晓玲律师则告诉媒体，她已关注到，并录屏。 张晓玲表示，"我非常期待他们起诉我。目前还没看到对方发来的起诉状，没有接到任何通知。但已做 好100%的准备，随时应诉。" "体检不等于看病诊断" 发布会现场，爱康集团创始人、董事长兼CEO张黎刚提供了一组数字——中国每一年确诊的癌症患者大 约有480万 ...

Core Viewpoint - The company Aikang Guobin is facing public scrutiny and legal action following allegations from a client, Ms. Zhang, who claims that her cancer was not detected during ten years of health check-ups, leading to a lawsuit against her for defamation [2][6]. Group 1: Company Response - Aikang Guobin held a media briefing to address the allegations, stating that Ms. Zhang's health check on October 9, 2023, indicated a "possible renal hamartoma," which suggests a potential cancer diagnosis [2][3]. - The company emphasized that Ms. Zhang's health checks were part of a basic package provided by the Beijing Bar Association, and she had not purchased any additional services except in 2017 [3]. - Aikang Guobin's CEO, Zhang Ligang, commented on public misconceptions regarding the effectiveness of low-cost health checks, questioning the expectation that a basic check costing a few hundred yuan could detect all diseases [11]. Group 2: Public Reaction and Concerns - Public skepticism arose regarding the value of health checks if they fail to detect serious conditions, with many questioning the purpose of offering such services [3][11]. - Ms. Zhang publicly demanded transparency from Aikang Guobin, requesting the release of her past ultrasound results and the qualifications of the personnel involved in her checks [6][11]. - Complaints against Aikang Guobin have surged, with over a thousand reports on platforms like Black Cat Complaints, citing issues such as inaccurate results and misleading practices [14]. Group 3: Industry Context - The incident has highlighted broader concerns within the health check industry, with previous allegations of malpractice and the existence of "fake health checks" being raised by industry insiders [14]. - The CEO's past revelations about the industry's integrity have come back to haunt him, as the company now faces a "crisis of trust" among the public [14].

超声与癌胚抗原争议 爱康集团体检超声专业组组长黄英对2023年10月张女士在爱康集团进行的超声报告进行了解读。她指出，张女士对外声称的2023年的超声检查描述"右肾钙 化灶、有低回声"属于编造，与其实际的超声报告不符。只要张女士提供书面授权，爱康集团可以直接对外公布张女士的超声检查的具体描述。 关于张女士所述"癌胚抗原（CEA）"检测正常一事，爱康集团副总裁汪朝晖进行回应，表示肾癌早期诊断主要依赖影像学（CT/MRI）而非血液检测（美国 NCCN指南2024）。癌胚抗原（CEA）主要用于结直肠癌、胃癌等消化道肿瘤辅助诊断和病情监测。2022版《肾细胞癌诊疗指南》明确指出，"目前尚无公 认的用于肾细胞癌早期辅助诊断的血清肿瘤标志物"，即CEA与肾细胞癌筛查无医学关联性，不能用于是否存在肾细胞癌的风险评估。 对张女士提出的"假体检"指控，汪朝晖在说明会上进行了否认。他现场展示了张女士历次体检中癌胚抗原（CEA）检测的脱敏质量控制图，并强调"所有质 控数据均可在爱康存储系统中完全追溯，随时可提交政府主管部门核查"，不存在任何"假体检"的可能。 张女士十年检测数据已上交 7月30日，爱康集团在京召开媒体说明会，就近期 ...

凤凰网财经讯 7月30日上午，爱康集团举行媒体说明会，针对此前与张女士的癌症检查纠纷，爱康集团 资深副总裁周晓江宣布，已向法院提起诉讼，法院已正式立案受理。爱康集团董事长张黎刚表示，为了 维护爱康15000名员工的尊严，为了给行业正名，爱康不得不做出这个非常艰难的决定。 随后，爱康体检事件当事人@张晓玲律师再发微博喊话爱康国宾:"别遮遮掩掩的了，把我的10年超声检 查公布出来、给我检查的人员名单和资质公布出来、第三方是谁公布出来、结果公布出来，起诉内容公 布出来，我没也别整假患者、伪专家了!"她还表示，自己也没有收到爱康起诉的内容。 在上午举行的发布会上，爱康集团创始人、董事长兼CEO张黎刚表示，体检不等于看病诊断，其服务模 式不同于专科医生接诊，可以说是由体检套餐决定的，最主要的功能是帮助受检者发现疾病的蛛丝马 迹，后续找专科医生做进一步的诊断，而非替代临床诊断。因此，无论是在独立的体检中心还是在三甲 医院的体检中心，服务模式都是一样的。预防是最为经济有效的健康管理策略。健康体检作为预防医疗 的核心手段之一，一直以来都在发挥着积极的作用。 ...